

AMENDMENTS TO THE SPECIFICATION

1. Amend the paragraph beginning at page 6, line 29, as follows:

FIGURES 3A-B depicts the composition of rgp120 and sgp160 immunogens used in the vaccination described in Example 1.

2. Amend the paragraph beginning at page 7, line 31, as follows:

FIGURES 6A-B shows the production of antibodies to rgp120 and sgp160 in animals immunized with candidate HIV-1 vaccines. Chimpanzees were immunized with 300µg per dose of rgp160 (x-247 and x-261), rgp120 (x262 and x-265) or herpes simplex virus glycoprotein D (x-246), at times 0, 4 weeks, and 32 weeks (arrows). All immunogens were incorporated in aluminum hydroxide adjuvant containing 2 mg equivalents of Al^{+3} per mg of protein. Blood was taken at the time points indicated, and the sera were analyzed for antibodies to rgp120 or sgp160 in the assays described ~~for the~~ in each of the specific panel descriptions. All animals were challenged by intravenous injection of 40 TCID₅₀ units of HIV-1 at 35 weeks. The open and closed squares represent the rgp120 immunized animals, x262 and x265, respectively. The open and closed circles represent the rsgp160 immunized animals, x247 and x261, respectively. The control animal, x246, is represented by open triangles.

3. Amend the paragraph beginning at page 8, line 25, as follows:

FIGURES 8A-B shows antibodies that neutralize HIV-1 infectivity *in vitro* and bind to the major type specific neutralizing determinant (MND). Open and closed squares represent sera obtained from the rgp120 immunized animals 262 and 265, respectively. The open and closed circles represent sera obtained from the rsgp160 immunized animals, 247 and 261, respectively. The open triangle represents the control animal (x246).